Table 3 Proteasome small molecule inhibitor of B5 protease for cancer treatment.
From: RNA-binding protein 39: a promising therapeutic target for cancer
Modulators | Condition | Clinical Stage | Refs |
|---|---|---|---|
Bortezomib + Daunorubicin + Cytarabine | Acute myeloid leukemia | Phase 1 | [1] |
Bortezomib + Decytabine | Acute myeloid leukemia, Myeloma malignancy | Phase 2 | [2] |
Bortezomib + SAHA | Phase 2 suspended | [3] | |
Bortezomib | Myeloma malignancy | Phase 1 | [4] |
Carlfizomib | Myeloma malignancy | Phase 1 | [5] |
Ixazomib | Myeloma malignancy | Phase 1 | [6] |
Marizomib | Myeloma malignancy, mantle cell lymphoma, chronic and acute lymphocytic leukemia, colorectal and pancreatic cancer models | Phase 3, recruiting | [7] |
Delanzomib | Myeloma malignancy and other malignancies | Phase 1, Phase 2, terminated | [8] |
